Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Investor Update
Get the latest updates from Investor Update directly as they happen.
Follow now 563 followers
Latest posts
Last updated about 15 hours ago
Roche receives FDA clearance for Elecsys® pTau217, advancing Alzheimer’s disease assessment across primary and specialty care
about 16 hours ago
First and only FDA-cleared, single-biomarker blood test supporting both rule-in and rule-out...
Invitation to Roche Pharma Day 2026
12 days ago
The Roche Investor Relations team would like to invite you to the...
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
21 days ago
Dear Investor, Please find attached a press release from our partner Nurix...
CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)
about 1 month ago
Susvimo is the first and only continuous delivery treatment that offers an...
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc
about 1 month ago
Group sales were +6% at constant exchange rates (CER)1, -2% when reported...
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc
about 1 month ago
Group sales were +6% at constant exchange rates (CER)1, -2% when reported...
Reminder: Invitation to Roche’s Half Year Results 2026 Presentation
about 1 month ago
Roche will publish its Half Year Results of 2026 prior to the...
FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for adults with primary membranous nephropathy
about 1 month ago
Priority Review decision is based on phase III MAJESTY results, where Gazyva/Gazyvaro...
Roche receives CE Mark for blood test to identify tuberculosis infection
about 2 months ago
The Elecsys IGRA TB test expands global access to tuberculosis infection testing...
Roche introduces cobas Hepatitis D Virus (HDV) test, the first fully automated diagnostic solution to identify the most severe form of viral hepatitis
about 1 month ago
The new test enables clinicians to reliably diagnose HDV and monitor patients’...
Roche presents new data in Alzheimer’s disease from across its integrated pharmaceutical and diagnostics portfolio at AAIC
about 2 months ago
Five oral presentations in a Featured Research Session will highlight trontinemab, including...
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer
about 2 months ago
Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated...